Generic Vuity Availability - Drugs.com (2024)

Last updated on Mar 6, 2024.

Vuity is a brand name of pilocarpine ophthalmic, approved by the FDA in the following formulation(s):

VUITY (pilocarpine hydrochloride - solution;ophthalmic)

Manufacturer: ABBVIE
Approval date: October 28, 2021
Strength(s): 1.25% ^[RLD]

Has a generic version of Vuity been approved?

No. There is currently no therapeutically equivalent version of Vuity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vuity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Presbyopia treatments
Patent 10,610,518
Issued: April 7, 2020
Inventor(s): Robinson Michael R. & Dibas Mohammed & Giyanani Jaya & Gore Anuradha & Lee Sungwook & Liu Haixia & Morgan Aileen & Zhou Jihao
Assignee(s): ALLERGAN, INC.
Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
See Also
Getting Your Patient Started With Upneeq - Upneeq Upneeq Prices, Coupons, Copay & Patient Assistance - Drugs.com Can This Eye Drop Make You Look Dramatically More Awake?How To Fix Droopy Eyelids, Circles and Sags
Patent expiration dates:
- April 24, 2039
  ✓
  Patent use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
- April 24, 2039
  ✓
  Patent use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
- April 24, 2039
  ✓
  Patent use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
Presbyopia treatments
Patent 11,285,134
Issued: March 29, 2022
Inventor(s): Robinson Michael R. & Dibas Mohammed & Giyanani Jaya & Gore Anuradha & Lee Sungwook & Liu Haixia & Morgan Aileen & Zhou Jihao
Assignee(s): ALLERGAN, INC.
Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
See Also
Upneeq Application and TreatmentInformation | Upneeq
Patent expiration dates:
- April 24, 2039
  ✓
  Patent use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
- April 24, 2039
  ✓
  Patent use: TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
- April 24, 2039
  ✓
  Patent use: USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 28, 2024 - NEW PRODUCT
- March 28, 2026 - ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS

More about Vuity (pilocarpine ophthalmic)

Check interactions
Compare alternatives
Drug images
Side effects
Dosage information
During pregnancy
FDA approval history
Breastfeeding
En español

Patient resources

Vuity drug information

Other brands

Pilocar, Isopto Carpine, Qlosi, Pilopine HS, Ocu-Carpine

Professional resources

Vuity Eye Drops prescribing information
Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate (AHFS Monograph)

Other brands

Isopto Carpine

Related treatment guides

Presbyopia

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circ*mstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circ*mstances.

Medical Disclaimer